Short answer
Twist Bioscience Corp (TWST) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $118M (up 23.2% year over year) with net income of −$35M.
Q2 2026 key financials · XBRL
- Revenue
- $118M
- +23.2% YoY · +6.9% QoQ
- Net income
- −$35M
- −271.9% YoY · +20.4% QoQ
- Operating margin
- -30.6%
- EPS (diluted)
- −$0.57
- −267.6% YoY · +19.7% QoQ
Source: XBRL data from the Twist Bioscience Corp (TWST) Q2 2026 10-Q on SEC EDGAR. USD.
Twist Bioscience Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $118.4M, up 23% YoY from $96.1M, led by DNA synthesis and protein solutions growth of 39%
- Gross margin 52.8% vs 53.4% YoY, primarily due to customer mix
- NGS applications largest product line at $61.8M, 52% of quarterly revenue; DNA synthesis and protein solutions $56.6M
- Cash and short-term investments $166.8M; nine-month operating cash use $41.3M vs $35.8M
- Outlook: SG&A expected to moderate in Q4 fiscal 2026; liquidity sufficient for more than 12 months, with $200.0M ATM capacity unused
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and signatures only
- Insider selling risk: CEO trading plan covering approximately 624,134 shares
- Insider selling risk: COO trading plan covering up to 78,355 shares
- Insider selling risk: Director trading plan covering up to 18,417 shares
- Financing risk: June 18, 2026 sales agreement with TD Securities (USA) LLC
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Twist Bioscience Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.